Literature DB >> 21173173

Comparative efficacy and safety of moxifloxacin and clindamycin in the treatment of odontogenic abscesses and inflammatory infiltrates: a phase II, double-blind, randomized trial.

Georg Cachovan1, Rainer H Böger, Ina Giersdorf, Olaf Hallier, Thomas Streichert, Munif Haddad, Ursula Platzer, Gerhard Schön, Karl Wegscheider, Ingo Sobottka.   

Abstract

Moxifloxacin penetrates well into oromaxillary tissue and covers the causative pathogens that show an increasing resistance to standard antibiotics. Clinical reports suggest that moxifloxacin may be effective for the treatment of odontogenic infections that can lead to serious complications. The objective of this prospective, randomized, double-blind, multicenter study was to compare the efficacies and safeties of moxifloxacin and clindamycin for the medical treatment of patients with gingival inflammatory infiltrates and as an adjuvant therapy for patients with odontogenic abscesses requiring surgical treatment. Patients received either 400 mg moxifloxacin per os once daily or 300 mg clindamycin per os four times daily for 5 days consecutively. The primary efficacy endpoint was the percent reduction in patients' perceived pain on a visual analogue scale at days 2 to 3 from baseline. Primary analysis included 21 moxifloxacin- and 19 clindamycin-treated patients with infiltrates and 15 moxifloxacin- and 16 clindamycin-treated patients with abscesses. The mean pain reductions were 61.0% (standard deviation [SD], 46.9%) with moxifloxacin versus 23.4% (SD, 32.1%) with clindamycin (P = 0.006) for patients with infiltrates and 55.8% (SD, 24.8%) with moxifloxacin versus 42.7% (SD, 48.5%) with clindamycin (P = 0.358) for patients with abscesses. A global efficacy assessment at days 2 to 3 and 5 to 7 showed faster clinical responses with moxifloxacin in both abscess and infiltrate patients. Rates of adverse events were lower in moxifloxacin- than in clindamycin-treated patients. In patients with inflammatory infiltrates, moxifloxacin was significantly more effective in reducing pain at days 2 to 3 of therapy than clindamycin. No significant differences between groups were found for patients with odontogenic abscesses.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21173173      PMCID: PMC3067083          DOI: 10.1128/AAC.01267-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  24 in total

1.  In vitro activity of moxifloxacin against bacteria isolated from odontogenic abscesses.

Authors:  Ingo Sobottka; Georg Cachovan; Enno Stürenburg; M Oliver Ahlers; Rainer Laufs; Ursula Platzer; Dietrich Mack
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

2.  Antibiotic resistance of pathogenic bacteria from odontogenic infections in Taiwan.

Authors:  You Chan; Chi-Ho Chan
Journal:  J Microbiol Immunol Infect       Date:  2003-06       Impact factor: 4.399

3.  Changing clinical features of odontogenic maxillofacial infections.

Authors:  Lotta Seppänen; Riina Rautemaa; Christian Lindqvist; Anneli Lauhio
Journal:  Clin Oral Investig       Date:  2009-05-16       Impact factor: 3.573

4.  A comparison of pain rating scales by sampling from clinical trial data.

Authors:  E K Breivik; G A Björnsson; E Skovlund
Journal:  Clin J Pain       Date:  2000-03       Impact factor: 3.442

5.  Antibacterial activity of moxifloxacin against periodontal anaerobic pathogens involved in systemic infections.

Authors:  I Milazzo; G Blandino; R Musumeci; G Nicoletti; A M Lo Bue; A Speciale
Journal:  Int J Antimicrob Agents       Date:  2002-12       Impact factor: 5.283

6.  Efficacy of antibiotics to strains of periodontopathogenic bacteria within a single species biofilm - an in vitro study.

Authors:  S Eick; T Seltmann; W Pfister
Journal:  J Clin Periodontol       Date:  2004-05       Impact factor: 8.728

7.  Efficacy and safety of sequential intravenous/oral moxifloxacin vs intravenous/oral amoxicillin/clavulanate for complicated skin and skin structure infections.

Authors:  R Vick-Fragoso; G Hernández-Oliva; J Cruz-Alcázar; C F Amábile-Cuevas; P Arvis; P Reimnitz; J R Bogner
Journal:  Infection       Date:  2009-09-18       Impact factor: 3.553

8.  Penetration of moxifloxacin into healthy and inflamed subcutaneous adipose tissues in humans.

Authors:  Christian Joukhadar; Heino Stass; Ulrike Müller-Zellenberg; Edith Lackner; Florian Kovar; Erich Minar; Markus Müller
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

Review 9.  The clinical significance of anaerobic bacteria in acute orofacial odontogenic infections.

Authors:  Panagiotis K Stefanopoulos; Alexandros E Kolokotronis
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  2004-10

10.  Penetration of moxifloxacin into bone evaluated by Monte Carlo simulation.

Authors:  Cornelia B Landersdorfer; Martina Kinzig; Friedrich F Hennig; Jürgen B Bulitta; Ulrike Holzgrabe; George L Drusano; Fritz Sörgel; Johannes Gusinde
Journal:  Antimicrob Agents Chemother       Date:  2009-02-17       Impact factor: 5.191

View more
  11 in total

1.  [Dentogenic infections-part I: the significance of bacterial isolation of dentogenic infections under routineous conditions].

Authors:  Alexander W Eckert; Louise Just; Dorothea Wilhelms; Johannes Schubert
Journal:  Wien Med Wochenschr       Date:  2012-06-05

Review 2.  Microbiology and treatment of acute apical abscesses.

Authors:  José F Siqueira; Isabela N Rôças
Journal:  Clin Microbiol Rev       Date:  2013-04       Impact factor: 26.132

3.  Microbiological analysis of a prospective, randomized, double-blind trial comparing moxifloxacin and clindamycin in the treatment of odontogenic infiltrates and abscesses.

Authors:  Ingo Sobottka; Karl Wegscheider; Ludwig Balzer; Rainer H Böger; Olaf Hallier; Ina Giersdorf; Thomas Streichert; Munif Haddad; Ursula Platzer; Georg Cachovan
Journal:  Antimicrob Agents Chemother       Date:  2012-02-21       Impact factor: 5.191

4.  Is the penetration of clindamycin into the masseter muscle really enough to treat odontogenic infections?

Authors:  Paula I Faggion; Gabriela Isoton; Eduarda Possa; Leandro Tasso
Journal:  Clin Oral Investig       Date:  2020-10-31       Impact factor: 3.573

5.  Assessment of Severity of Illness and Monitoring Response to Treatment of Odontogenic Space Infection Using Serum Prealbumin.

Authors:  Peter Olalekan Adeosun; Olawunmi Adedoyin Fatusi; Tewogbade Adeoye Adedeji
Journal:  J Maxillofac Oral Surg       Date:  2018-03-26

6.  Bisphosphonates in dentistry: Historical perspectives, adverse effects, and novel applications.

Authors:  Parish P Sedghizadeh; Shuting Sun; Allan C Jones; Esmat Sodagar; Philip Cherian; Casey Chen; Adam F Junka; Jeffrey D Neighbors; Charles E McKenna; R Graham G Russell; Frank H Ebetino
Journal:  Bone       Date:  2021-03-20       Impact factor: 4.626

Review 7.  Oral Antibiotic for Empirical Management of Acute Dentoalveolar Infections-A Systematic Review.

Authors:  Leanne Teoh; Monique C Cheung; Stuart Dashper; Rodney James; Michael J McCullough
Journal:  Antibiotics (Basel)       Date:  2021-02-28

8.  Phenotype, genotype, and antibiotic susceptibility of Swedish and Thai oral isolates of Staphylococcus aureus.

Authors:  Susanne Blomqvist; Åsa Leonhardt; Pratanporn Arirachakaran; Anette Carlen; Gunnar Dahlén
Journal:  J Oral Microbiol       Date:  2015-04-23       Impact factor: 5.474

Review 9.  Dental abscess: A microbiological review.

Authors:  S Krishna Prakash
Journal:  Dent Res J (Isfahan)       Date:  2013-09

10.  Moxifloxacin versus Clindamycin/Ceftriaxone in the management of odontogenic maxillofacial infectious processes: A preliminary, intrahospital, controlled clinical trial.

Authors:  Hansel Gómez-Arámbula; Antonio Hidalgo-Hurtado; Rosaura Rodríguez-Flores; Ana-María González-Amaro; Arturo Garrocho-Rangel; Amaury Pozos-Guillén
Journal:  J Clin Exp Dent       Date:  2015-12-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.